Barr Pharmaceuticals Wins Battle to Acquire Pliva

Excerpt from our Wall Street Breakfast, a one-page summary of this morning's key market-moving and stock-moving stories:

Barr Buys Over 70% of Pliva Shares [Business Week]

Summary: Barr Pharmaceuticals Inc. has succeeded in acquiring over 70% of generic drug manufacturer Pliva DD, based in Zagreb, Croatia, ending its feud with Iceland-based Actavis Group HF. Barr's paid 820 kuna ($139)/share. It was not immediately clear who sold the shares, although Croatian media reported that at least two banks, and the government, which controlled 18% of Pliva, were among the sellers. There was even speculation that Actavis, which had acquired 21% of Pliva during its battle with Barr, might have sold some of them.
Related links: Background: Barr Labs On the Road to Zagreb (BRL)
Potentially impacted stocks and ETFs: Barr Pharmaceuticals Inc. (BRL). Generic drugmakers ranked by sales: Teva Pharmaceutical Industries Ltd. (TEVA), Watson Pharmaceuticals Inc. (WPI), Alpharma Inc. (ALO), King Pharmaceuticals Inc. (KG), Mylan Laboratories Inc. (MYL), Andrx Group (ADRX), Pfizer Inc. (PFE). ETFs: SPDR Pharmaceuticals ETF (XPH) has a 5% holding in BRL.

Seeking Alpha's Wall Street Breakfast summarizes today's key market- and stock-moving news. Receive it by email every weekday morning (free/no spam).

Seeking Alpha is not affiliated with Business Week.